 Ridinilazole showed a sustained clinical response (SCR).The study was a double-blind, randomized, active-controlled, multi-center trial with 100 patients comparing ridinilazole to vancomycin.Adults in the trial had a clinical diagnosis of CDI with no more than 24 hours of antimicrobial treatment and no more than 3 cases of CDI in the previous 12 months.